Influnce of MTHFR gene polymorphism on folicacid in lowering plasma homocyteine
10.3969/j.issn.1006-5725.2014.07.025
- VernacularTitle:MTHFR基因型对叶酸降同型半胱氨酸效果的影响
- Author:
Peng LI
;
Ling JIA
- Publication Type:Journal Article
- Keywords:
Coronary disease;
Methylene tetrahydrofolate reductase;
Homocysteine;
Folic acid
- From:
The Journal of Practical Medicine
2014;(7):1091-1093
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the impact of methylene tetrahydrofolate reductase (MTHFR) gene polymorphism on folicacid for lowering plasma level of homocysteine in elderly patients with coronary heart disease (CHD). Methods In the first affiliated hospital of Zhengzhou university,a total of 180 elderly patients with CHD were randomized to two groups. The study group (91 ptients) received folicacid 5mg once daily and the control group (89 patients) received no folic acid. 8 weeks after treatment, the changes in plasma Hcy were observed and analyzed by MTHFR genotypes (TT vs. CC vs. CT). Results Plasma Hcy of the three genotypes had a statistical significance at the baseline (P<0.001), among which plasma Hcy level was the hightest in patients with genotype TT, while it had on difference in genotypes CC and CT (P = 0.057). 8 weeks after treatment, plasma Hcy level declined up to 24%in the patients with genotype TT in the study group, while it decreased about 6%and 15%in patients with genotype CC or CT, separately. Hcy level was slightly decreased in the patients with genotype CC, CT, or TT in the control group. Conclusions Plasma Hcy level differs statistically in three genotypes, and it is the highest in genotyp TT. Folicacid can effectively lower the level of plasma Hcy in elderly patients with CHD, especially those with genotype TT.
